Comparative Efficacy and Side Effects of the Treatment of Euthyroid Goiter with Levo-Thyroxine or Triiodothyroacetic Acid

Journal of Clinical Endocrinology and Metabolism

Volumn 88, Issue 11, 2003, Pages 5287-5292

  Brenta, G ^a   Schnitman, M ^a   Fretes, O ^a   Facco, E ^a   Gurfinkel, M ^a   Damilano, S ^a   Pacenza, N ^a   Blanco, A ^a   Gonzalez, E ^b   Pisarev, M A ^c,d  

^a HOSPITAL FRANCÉS   (Argentina)

^b DEPARTAMENTO DE FÍSICA   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d NONE   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYPYRIDINOLINE; HIGH DENSITY LIPOPROTEIN; LEVOTHYROXINE; LOW DENSITY LIPOPROTEIN; OSTEOCALCIN; THYROTROPIN; TIRATRICOL; TRIACYLGLYCEROL;

ADULT; ARTICLE; ASTHENIA; BONE DENSITY; BONE MINERAL; CALCIUM BLOOD LEVEL; CHRONIC DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXPERIENCE; FEMALE; FEMUR; GASTROINTESTINAL SYMPTOM; GOITER; HAIR LOSS; HEADACHE; HEART PALPITATION; HORMONE INHIBITION; HOT FLUSH; HUMAN; HYPERTENSION; INSOMNIA; LUMBAR VERTEBRA; NERVOUSNESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STUDENT T TEST; THYROIDITIS; TREMOR;

ADULT; BLOOD PRESSURE; BONE AND BONES; GOITER; HEART RATE; HUMANS; HYPOTHYROIDISM; LIVER; MALE; MIDDLE AGED; THYROID FUNCTION TESTS; THYROXINE; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 10744220388     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-030095     Document Type: Article

References (36)

1. Gharib H, Mazzaferri EL 1998 Thyroxine suppressive therapy in patients with nodular disease. Ann Int Med 18:386-394
2. Paggi A, Persegani-Trimarchi C, Russo P, Mastropasqua M, Mosetti MA, Losi T, Leri O 1999 Solitary nodular disease and multinodular goiter: a retrospective study on suppressive versus replacement levothyroxine therapy. Endocr Res 25:229-238
3. Reverter JL, Lucas A, Salinas I, Audi L, Foz M, Sanmarti A 1992 Suppressive therapy with levothyroxine for solitary thyroid nodules. Clin Endocrinol (Oxf) 38:25-28
4. Gullu S, Gurses A, Baskal N, Uysal AR, Kamel AN, Erdogan G 1999 Suppressive therapy with levothyroxine for euthyroid diffuse and nodular goiter. Endocr J 46:221-226
5. Zelmanovitz F, Genro S, Gross JL 1998 Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analysis. J Clin Endocrinol Metab 83:3881-3885
6. Faber J, Galloe AM 1998 Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a metaanalysis. Eur J Endocrinol 130:350-356
7. Toivonen J, Tahtela R, Laitinen K, Risteli J, Valimaki MJ 1998 Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy. Eur J Endocrinol 138: 667-673
8. Taimela E, Taimela S, Nikkanen V, Irjala K 1994 Accelerated bone degradation in thyroid carcinoma patients during thyroxine treatment, measured by determination of the carboxy terminal telopeptide region of type I collagen in serum. Eur J Clin Chem Clin Biochem 32:827-831
9. Nakamura Y, Chopra I, Solomon DH 1978 An assessment of the concentration of acetic and propionic acid derivatives of 3,5,3′-triiodothyronine in human serum. J Clin Endocrinol Metab 46:91-97
10. Menegay C, Juge C, Burger AG 1989 Pharmacokinetics of 3,5,3′-triiodothyroacetic acid and its effects on serum TSH levels. Acta Endocrinol 121:651-658
11. 125I-triiodthyroacetic acid to measure nuclear thyroid hormone receptor. Endocr Res 12:37-47
12. Burger AG, Engler D, Sakoloff C, Staheli V 1979 The effects of tetraiodothyroacetic and triiodothyroacetic acids on thyroid function in euthyroid and hyperthyroid subjects. Acta Endocrinol 92:455-467
13. Bracco D, Morin O, Schutz Y, Liang H, Jequier E, Burger AG 1993 Comparison of the metabolic and endocrine effects of 3,5,3′- triiodothyroacetic acid and thyroxine. J Clin Endocrinol Metab 77:221-228
14. Medeiros-Neto G, Kallas WG, Knobel M, Cavaliere H, Mattar E 1980 Triac (3,5,3′-triiodothyroacetic acid) partially inhibits the thyrotropin response to synthetic thyrotropin releasing hormone in normal and thyroidectomized hypothyroid patients. J Clin Endocrinol Metab 50:223-225
15. Sherman SI, Ladenson PW 1992 Organ-specific effects of tiratricol: a thyroid hormone analog with hepatic non-pituitary superagonist effects. J Clin Endocrinol Metab 75:901-905
16. Lind P, Langsteger W, Koltringer P, Eber O 1989 3,5, 3′triiodothyroacetic acid (TRIAC) effects on pituitary thyroid regulation and on peripheral tissue parameters. Nuklearmedizin 28:217-220
17. Jaffiol C, Baldet L, Papachristou C, Bringer J 1988 Interet de l'acide triiodthyroacetique comme traitment freinateur de la secretion thyreotrope en pathologie thyroidienne. Presse Med 17:57-60
18. Brunn J, Block U, Ruf G, Bos I, Kunze WP, Scriba PC 1981 Volumetric analysis of thyroid lobes by real-time ultrasound. Dtsch Med Wochenschr 106:1338-1340
19. Brenta G, Schnitman M, Bonnahon LA, Besuschio S, Zuk CA, De Barrio G, Peruzzotti CH, Saubidet AG 2002 A simple skin marking technique as an option to optimize ultrasound guided thyroid nodules. Endocr Pract 8:5-9
20. Castro RM, Caraballo PJ, Morris JC 2002 Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. J Clin Endocrinol Metab 87:4154-4159
21. Gharib H, James EM, Charboneau WJ, Naessens JM, Offord KP, Gorman CA 1987 Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study. N Engl J Med 317:70-75
22. Hintze G, Emrich D, Kobberling J 1989 Treatment of endemic goitre due to iodine deficiency with iodine, levothyroxine or both: results of a multicentric trial. Eur J Clin Invest 19:527-534
23. Einenkel D, Bauch KH, Nenker G 1992 Treatment of juvenile goitre with levothyroxine, iodine or a combination of both: the value of ultrasound grey-scale analysis. Acta Endocrinol (Copenh) 127:301-306
24. 2 availability. Horm Metab Res 20:86-91
25. Kimura T, van Keymeulen A, Golstein J, Fusco A, Dumont JE, Roger PP 2001 Regulation of thyroid cell proliferation by TSH and other factors: a critical evaluation of in vitro models. Endocr Rev 22:631-656
26. Studer H, Derwahl M 1995 Mechanism of nonneoplastic endocrine hyperplasia-A changing concept: a review focused on the thyroid gland. Endocr Rev 16:411-426
27. Derwahl M, Broecker M, Kraiem Z 1999 Thyrotropin may not be a dominant growth factor in benign and malignant thyroid tumors. J Clin Endocrinol Metab 84:829-834
28. Juvenal GJ, Pisarev MA, Kleiman de Pisarev DL, Altschuler N 1981 Uptake, metabolism and action of triiodothyronine in calf thyroid slices. Mol Cell Endocrinol 22:31-40
29. 3H-uridine incorporation into thyroid RNA. Acta Endocrinol (Copenh) 9:316-322
30. 125I- triiodothyronine in calf thyroid. Horm Metab Res 18:318-322
31. Erkenbrack DE, Rosenberg LL 1986 Binding of thyroid hormones to nuclear extracts of thyroid cells. Endocrinology 119:311-317
32. Uzzan B, Campos J, Cucherat M, Nony P, Boissel JP, Perret GY 1996 Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81:4278-4289
33. Morita T, Tamai H, Oshima A 1989 Changes in serum thyroid hormone, thyrotrophin and thyroglobulin concentrations during thyroxine therapy in patients with solitary thyroid nodules. J Clin Endocrinol Metab 69:227-230
34. Burgi U, Scazziga BR, Rosselet PO, Burgi H, Studer H 1988 Can serum thyroglobulin predict the effect of thyroid hormone therapy on goiter growth? Acta Endocrinol 119:118-124
35. Muller Gartner HW, Schneider C 1988 3,5,3′triiodothyroacetic acid minimizes the pituitary thyrotropin secretion in patients on levo-thyroxine therapy after ablative therapy for differentiated thyroid carcinoma. Clin Endocrinol 28: 345-351
36. Jaffiol C, Daures JP, Nsakala N, Guerenova J, Baldet L 1995 Le controle a long terme du traitment médicale du cancer thyroidiene différencié. Ann Endocrinol (Paris) 56:119-126